Trial Profile
Observational Prospective Study to Assess the Safety and Effectiveness Profile of Beltavac® Polymerized With Alternaria Alternata
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Alternaria allergy immunotherapy (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Probelte Pharma
- 10 May 2023 Status changed from active, no longer recruiting to completed.
- 07 Feb 2023 Planned End Date changed from 30 Sep 2022 to 1 Oct 2023.
- 07 Feb 2023 Planned primary completion date changed from 30 Jun 2022 to 1 Jul 2023.